These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 18397661

  • 1. [Osteoporosis--new therapeutic possibilities. The Danish Bone Society].
    Langdahl BL, Rejnmark L, Dansk Knoglemedicinsk Selskab.
    Ugeskr Laeger; 2008 Mar 17; 170(12):1043. PubMed ID: 18397661
    [No Abstract] [Full Text] [Related]

  • 2. [New development in bisphosphonate treatment. Review of effect on bone metabolism by minodronic acid in primary osteoporosis].
    Fukunaga M.
    Clin Calcium; 2009 Jan 17; 19(1):63-73. PubMed ID: 19122266
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Bone diseases with Pain. Osteoporosis].
    Hayashi Y.
    Clin Calcium; 2007 Apr 17; 17(4):606-12. PubMed ID: 17404492
    [Abstract] [Full Text] [Related]

  • 5. [Measurement of bone mineral density is unnecessary for monitoring of bisphosphonate treatment].
    Nishida A, Ito M.
    Clin Calcium; 2011 Jan 17; 21(1):120-3. PubMed ID: 21187605
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Zoledronic acid for preventing fractures].
    Traut V.
    Internist (Berl); 2008 Aug 17; 49(8):1002; author reply 1002. PubMed ID: 18545977
    [No Abstract] [Full Text] [Related]

  • 9. Vitamin D receptor genotypes and response to zoledronic acid therapy in thalassemia-induced osteoporosis.
    Otrock ZK, Mahfouz RA, Charafeddine KM, Rayes RF, Zahed LF, Taher AT.
    Ann Hematol; 2008 Nov 17; 87(11):947-8. PubMed ID: 18443790
    [No Abstract] [Full Text] [Related]

  • 10. Zoledronic acid--once-yearly. Corticosteroid-induced osteoporosis: no benefit.
    Prescrire Int; 2010 Apr 17; 19(106):63. PubMed ID: 20568485
    [No Abstract] [Full Text] [Related]

  • 11. Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS).
    Sanders J, Crawford B, Gibson J, Joy Ho P, Iland H, Joshua D.
    Int J Lab Hematol; 2007 Oct 17; 29(5):395-7. PubMed ID: 17824924
    [No Abstract] [Full Text] [Related]

  • 12. [Better informed decisions in the management of osteoporosis].
    Alonso-Coello P, Bonfill X.
    Reumatol Clin; 2011 Oct 17; 7(1):1-2. PubMed ID: 21794771
    [No Abstract] [Full Text] [Related]

  • 13. [New bone density conservation agents for osteoporosis under research and development: Zoledronate].
    Wada S, Fukawa T, Kamiya S.
    Nihon Rinsho; 2007 Nov 28; 65 Suppl 9():421-5. PubMed ID: 18161143
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Bisphosphonate therapy for osteoporosis: the long and short of it.
    Compston JE, Bilezikian JP.
    J Bone Miner Res; 2012 Feb 28; 27(2):240-2. PubMed ID: 22271395
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Bisphosphonate-induced fractures: nature strikes back?
    Aspenberg P.
    Acta Orthop; 2008 Aug 28; 79(4):459-60. PubMed ID: 18766476
    [No Abstract] [Full Text] [Related]

  • 19. [Treatment goals of osteoporosis].
    Hosoi T.
    Clin Calcium; 2014 Mar 28; 24(3):385-9. PubMed ID: 24576935
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.